212 related articles for article (PubMed ID: 11437862)
1. Effect of troglitazone on urinary albumin excretion and serum type IV collagen concentrations in Type 2 diabetic patients with microalbuminuria or macroalbuminuria.
Nakamura T; Ushiyama C; Suzuki S; Shimada N; Sekizuka K; Ebihara L; Koide H
Diabet Med; 2001 Apr; 18(4):308-13. PubMed ID: 11437862
[TBL] [Abstract][Full Text] [Related]
2. Effect of troglitazone on microalbuminuria in patients with incipient diabetic nephropathy.
Imano E; Kanda T; Nakatani Y; Nishida T; Arai K; Motomura M; Kajimoto Y; Yamasaki Y; Hori M
Diabetes Care; 1998 Dec; 21(12):2135-9. PubMed ID: 9839106
[TBL] [Abstract][Full Text] [Related]
3. Comparative effects of pioglitazone, glibenclamide, and voglibose on urinary endothelin-1 and albumin excretion in diabetes patients.
Nakamura T; Ushiyama C; Shimada N; Hayashi K; Ebihara I; Koide H
J Diabetes Complications; 2000; 14(5):250-4. PubMed ID: 11113686
[TBL] [Abstract][Full Text] [Related]
4. Troglitazone decreases serum uric acid concentrations in type II diabetic patients and non-diabetics.
Iwatani M; Wasada T; Katsumori K; Watanabe-Takahashi C; Kamatani N; Iwamoto Y
Diabetologia; 2000 Jun; 43(6):814-5. PubMed ID: 10907128
[No Abstract] [Full Text] [Related]
5. Pioglitazone reduces urinary podocyte excretion in type 2 diabetes patients with microalbuminuria.
Nakamura T; Ushiyama C; Osada S; Hara M; Shimada N; Koide H
Metabolism; 2001 Oct; 50(10):1193-6. PubMed ID: 11586492
[TBL] [Abstract][Full Text] [Related]
6. Thiazolidinedione derivatives ameliorate albuminuria in streptozotocin-induced diabetic spontaneous hypertensive rat.
Yamashita H; Nagai Y; Takamura T; Nohara E; Kobayashi K
Metabolism; 2002 Apr; 51(4):403-8. PubMed ID: 11912544
[TBL] [Abstract][Full Text] [Related]
7. Asian multicenter trials on urinary type IV collagen in patients with diabetic nephropathy.
Tomino Y; Suzuki S; Azushima C; Shou I; Iijima T; Yagame M; Wang LN; Chen HC; Lai KN; Tan SY; Kim MJ
J Clin Lab Anal; 2001; 15(4):188-92. PubMed ID: 11436201
[TBL] [Abstract][Full Text] [Related]
8. Serum type IV collagen in diabetic patients at risk for nephropathy.
Cohen MP; Shearman CW; Lautenslager GT
Diabetes Care; 2001 Aug; 24(8):1324-7. PubMed ID: 11473064
[TBL] [Abstract][Full Text] [Related]
9. Deterioration of glycemic control after long-term treatment with troglitazone in nonobese type 2 diabetic patients.
Murase Y; Wakasugi T; Yagi K; Mabuchi H
Diabetes Care; 2000 Jan; 23(1):131-2. PubMed ID: 10857989
[No Abstract] [Full Text] [Related]
10. Pioglitazone-induced hepatic injury in a patient previously receiving troglitazone with success.
Nagasaka S; Abe T; Kawakami A; Kusaka I; Nakamura T; Ishikawa S; Saito T; Ishibashi S
Diabet Med; 2002 Apr; 19(4):347-8. PubMed ID: 11943013
[No Abstract] [Full Text] [Related]
11. Troglitazone: a review of its use in the management of type 2 diabetes mellitus.
Plosker GL; Faulds D
Drugs; 1999 Mar; 57(3):409-38. PubMed ID: 10193691
[TBL] [Abstract][Full Text] [Related]
12. Long-term effects of troglitazone: open-label extension studies in type 2 diabetic patients.
Fonseca V; Foyt HL; Shen K; Whitcomb R
Diabetes Care; 2000 Mar; 23(3):354-9. PubMed ID: 10868865
[TBL] [Abstract][Full Text] [Related]
13. Effect of troglitazone in type 2 diabetes mellitus.
Gorson DM
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696655
[No Abstract] [Full Text] [Related]
14. Effect of troglitazone in type 2 diabetes mellitus.
Rusk MH
N Engl J Med; 1998 Aug; 339(6):406. PubMed ID: 9696656
[No Abstract] [Full Text] [Related]
15. Troglitazone (CS-045) ameliorates albuminuria in streptozotocin-induced diabetic rats.
Fujii M; Takemura R; Yamaguchi M; Hasegawa G; Shigeta H; Nakano K; Kondo M
Metabolism; 1997 Sep; 46(9):981-3. PubMed ID: 9284882
[TBL] [Abstract][Full Text] [Related]
16. Effect of troglitazone on body fat distribution in type 2 diabetic patients.
Mori Y; Murakawa Y; Okada K; Horikoshi H; Yokoyama J; Tajima N; Ikeda Y
Diabetes Care; 1999 Jun; 22(6):908-12. PubMed ID: 10372240
[TBL] [Abstract][Full Text] [Related]
17. Effect of troglitazone in insulin-treated patients with type II diabetes mellitus. Troglitazone and Exogenous Insulin Study Group.
Schwartz S; Raskin P; Fonseca V; Graveline JF
N Engl J Med; 1998 Mar; 338(13):861-6. PubMed ID: 9516220
[TBL] [Abstract][Full Text] [Related]
18. Troglitazone reduces hyperglycaemia and selectively acute-phase serum proteins in patients with Type II diabetes.
Ebeling P; Teppo AM; Koistinen HA; Viikari J; Rönnemaa T; Nissén M; Bergkulla S; Salmela P; Saltevo J; Koivisto VA
Diabetologia; 1999 Dec; 42(12):1433-8. PubMed ID: 10651262
[TBL] [Abstract][Full Text] [Related]
19. The short-term effect of a switch from glibenclamide to metformin on blood pressure and microalbuminuria in patients with type 2 diabetes mellitus.
Amador-Licona N; Guízar-Mendoza J; Vargas E; Sánchez-Camargo G; Zamora-Mata L
Arch Med Res; 2000; 31(6):571-5. PubMed ID: 11257323
[TBL] [Abstract][Full Text] [Related]
20. Short-term treatment with troglitazone decreases bone turnover in patients with type 2 diabetes mellitus.
Okazaki R; Miura M; Toriumi M; Taguchi M; Hirota Y; Fukumoto S; Fujita T; Tanaka K; Takeuchi A
Endocr J; 1999 Dec; 46(6):795-801. PubMed ID: 10724355
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
